BPCR:LSE:LSE-BioPharma Credit PLC (USD)

COMMON STOCK | Asset Management |

Last Closing

USD 0.834

Change

0.00 (0.00)%

Market Cap

USD 102.89B

Volume

0.35M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap
FP:LSE Fondul Proprietatea S.A. GDR

N/A

USD 264.18B
BHMU:LSE BH Macro Limited

+0.06 (+1.60%)

USD 175.21B
MNTN:LSE Schiehallion Fund Ltd

+0.06 (+6.32%)

USD 92.77B
TFG:LSE Tetragon Financial Group Ltd

N/A

USD 83.64B
RTW:LSE RTW Venture Fund Ltd

-0.01 (-0.65%)

USD 53.54B
TPOU:LSE Third Point Investors Limited

+0.50 (+2.27%)

USD 53.53B
SHIP:LSE Tufton Oceanic Assets Ltd

-0.01 (-0.83%)

USD 35.22B
TMI:LSE Taylor Maritime Investments Lt..

+0.01 (+0.51%)

USD 32.69B
III:LSE 3I Group PLC

-18.00 (-0.58%)

USD 30.38B
FAIR:LSE Fair Oaks Income Limited

+0.01 (+1.82%)

USD 23.68B

ETFs Containing BPCR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Asset Management) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.71% 41% F 39% F
Dividend Return 5.61% 99% N/A 98% N/A
Total Return 4.89% 65% D 58% F
Trailing 12 Months  
Capital Gain -8.95% 28% F 26% F
Dividend Return 11.15% 99% N/A 99% N/A
Total Return 2.19% 54% F 42% F
Trailing 5 Years  
Capital Gain -20.95% 34% F 26% F
Dividend Return 37.29% 93% A 94% A
Total Return 16.34% 65% D 52% F
Average Annual (5 Year Horizon)  
Capital Gain -2.46% 32% F 32% F
Dividend Return 5.48% 55% F 59% D-
Total Return 7.95% 86% B+ 92% A
Risk Return Profile  
Volatility (Standard Deviation) 39.28% 44% F 23% F
Risk Adjusted Return 13.96% 58% F 52% F
Market Capitalization 102.89B 99% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.